The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.
In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of HER2 biology and explain why new testing and interpretation methods for HER2-low and ultralow expression in mBC are emerging. Through expert discussion, they explore key evidence driving this shift and what it means for clinical practice moving forward.
Learn More Here